27 studies found for:    " November 16, 2011":" December 16, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" November 16, 2011":" December 16, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: TVD;   Drug: NNRTI
2 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: RTV;   Drug: TVD;   Drug: PI
3 Active, not recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF;   Drug: Placebo to match E/C/F/TDF
4 Completed Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries
Conditions: Partner HIV Testing;   Couple HIV Counseling;   Couple Communication;   HIV Incidence
Intervention: Behavioral: Couple-oriented post-test HIV counseling
5 Active, not recruiting Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Conditions: Tobacco Cessation;   HIV;   AIDS
Interventions: Behavioral: Treatment as usual;   Behavioral: AIR (Aspirations, Inspiration, Respiration)
6 Recruiting Use of Incentives to Retain Drug Users in HIV Therapy
Condition: HIV Infection
Intervention: Other: monetary reinforcer
7 Completed Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Condition: HIV-1 Infection
Interventions: Drug: Isentress® (Raltegravir, 400 mg every 12 hours);   Drug: Isentress® (Raltegravir, 400 every 12 hours)
8 Completed Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Conditions: Human Immunodeficiency Virus Infection;   Sexually Transmitted Diseases
Interventions: Behavioral: Men Making a Difference HIV/STD Risk Reduction Intervention;   Behavioral: Health Promotion Control
9 Not yet recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
10 Active, not recruiting Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
11 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
12 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
13 Terminated Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
14 Recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
15 Active, not recruiting
Has Results
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
16 Recruiting American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
Condition: HIV/AIDS-associated Fatigue
Interventions: Drug: American ginseng;   Dietary Supplement: Placebo for American ginseng
17 Recruiting WHC+ (Women's Health CoOp PLUS)
Conditions: HIV;   Sexual Risk;   Sexually Transmitted Diseases;   Substance Abuse;   Violence;   Victimization
Interventions: Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC);   Biological: Test, Treat, Retain(TTR) only
18 Active, not recruiting Early HIV Therapy in Patients With High CD4 Cell Counts
Condition: HIV
Interventions: Drug: Standard ART;   Drug: Study-Provided ART
19 Unknown  Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management
Condition: HIV
Intervention: Behavioral: VIH-TAVIE
20 Completed Antiretroviral Drug Interaction Study in Volunteers With HIV
Conditions: HIV;   PCP;   Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily;   Drug: Atovaquone 1500 mg twice daily

Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results
Indicates status has not been verified in more than two years